Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 December 2007

Therapeutic drug monitoring of sirolimus and everolimus

E.M. Billaud

Ann Transplant 2008; 13(1): 26-26 :: ID: 880180

Abstract

Sirolimus (SRL) (rapamycine) and everolimus (RAD), 40-hydroxy-rapamycine, were recently introduced as proliferation signal inhibitors (PSI) immunosuppressants, acting on the mTOR (target of rapamycine) IL2 synthesis. Due to different development strategies, SRL was registered in renal transplantation with steroids and cyclosporine (CyA) for the first three months, whereas RAD both in renal and cardiac transplantation with steroids and (reduced doses) CyA. Therapeutic drug monitoring (TDM) was recommended to control the enhancement of CyA nephrotoxicity and document RAD therapeutic detectable levels. Target trough concentration range were defined respectively as 3-8 and 4-12 ng/mL for RAD and SRL, the latest increased after CyA withdrawal [12-20]. Dose regimen are 2-5 mg QD (SRL) and 0.75 mg BID (RAD), taking in account the inhibition of CyA on PSI metabolism. Security profile exhibited hyperlipidemia, haematotoxicity, and more specific side effects (interstitial pneumopathy, lymphoceles and mucositis). Pharmacokinetics particularities of these lipophilic drugs resulted in long half-lives, poor bioavailability, intensive metabolism and numerous pharmacokinetic CYP3A4 drug interactions. Interindividual variability appeared more important than intraindividual. PSI exhibited similar pharmacodynamics but RAD appeared easiest to manage in clinical practice, due to its reduced halflife (30 h) as compared to SRL (60 h). TDM is performed using LC-MS/MS, but immunoassays are available from Abbott (MEIA, SRL) and Seradyn (Innofluor FPIA, RAD), exhibiting cross reactions (>80%) with metabolites and between PSI. International proficiency testing schemes are available (www.bioanalytics.uk). The place of these drugs in the immunosuppressive strategy has to be settled in the future, specially regarding delayed graft dysfunction prevention.

Keywords: Sirolimus, Everolimus, immunosuppressants

0 Comments

Most Viewed Current Articles

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

24 Aug 2021 : Review article  

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358